
    
      This is a randomized, double-blind, double-dummy, multi-centre parallel group study. Subjects
      who meet the eligilibilty criteria at Screening and meet the randomization criteria at the
      end of a 2-week Run-In period will enter a 12-week Treatment period. There will be a 7-day
      Follow-up period after the treatment period.
    
  